Portal de Periódicos da CAPES

Serum neurofilament light chain in progressive supranuclear palsy

2018; Elsevier BV; Volume: 56; Linguagem: Inglês

10.1016/j.parkreldis.2018.06.018

1873-5126

Laura Donker Kaat, Lieke Meeter, Wan Zheng Chiu, Shami Melhem, Agnita J.W. Boon, Kaj Blennow, Henrik Zetterberg, John C. van Swieten,

Neurological diseases and metabolism

Abstract Introduction Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. Methods Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. Results We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. Conclusion This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.